tradingkey.logo
tradingkey.logo
Search

Pacira Biosciences Inc

PCRX
Add to Watchlist
24.690USD
+0.210+0.86%
Close 09-17 16:00ET
982.42MMarket Cap
195.93P/E TTM

Pacira Biosciences Inc (PCRX) Revenue Performance

Updated: Jun 30, 2026

By Business

Annual
Annual
Quarterly
EXPAREL
ZILRETTA
iovera
Bupivacaine liposome injectable suspension
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
EXPAREL
575.13M(79.56%)
548.96M(78.74%)
538.12M(80.05%)
536.90M(80.84%)
506.51M(93.98%)
417.80M(97.93%)
ZILRETTA
116.63M(16.14%)
118.09M(16.94%)
111.10M(16.53%)
105.52M(15.89%)
12.68M(2.35%)
--(--)
iovera
24.18M(3.34%)
22.81M(3.27%)
19.68M(2.93%)
15.26M(2.30%)
16.16M(3.00%)
8.82M(2.07%)
Bupivacaine liposome injectable suspension
6.91M(0.96%)
7.32M(1.05%)
3.34M(0.50%)
6.48M(0.98%)
3.61M(0.67%)
--(--)
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.